Ibrutinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Lymphocytic Leukemia, Graft-versus-Host Disease, Chronic Graft-versus-Host Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Mantle Cell Lymphoma · Phase 3Diffuse Large B-Cell Lymphoma · Phase 3

Also approved (4)
US
  • Adult patients with Waldenström's macroglobulinemia (WM)
Product first approved 2014FDA label
JP
  • Treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Product first approved 2016PMDA
CA
  • IMBRUVICA (ibrutinib) is indicated: • for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion. Clinical effectiveness of IMBRUVICA in previously untreated adult patients with CLL with 17p deletion is based on the benefit observed in patients with CLL with 17p deletion who have received at least one prior therapy. Clinical trial data in previously untreated patients with CLL with 17p deletion are very limited. • in combination with obinutuzumab for the treatment of adult patients with previously untreated CLL,...
Product first approved 2014Health Canada
EU
  • Imbruvica in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (IMBRUVICA + R-CHOP) alternating with R-DHAP (or R-DHAOx) without Imbruvica, followed by Imbruvica monotherapy, is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplantation (ASCT).Imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory MCL.Imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is...
Product first approved 2014EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (31)
Chronic Graft-versus-Host Disease
NCT01804686 · Janssen Research & Development, LLC
2013-09-09 – 2029-12-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
What this study did
NCT03474679 · Janssen Pharmaceutical K.K.
2018-05-01 – 2021-11-29 · Graft vs Host Disease
What this study did
NCT02959944 · Pharmacyclics LLC.
2017-05-11 – 2021-07-12 · Chronic Graft Versus Host Disease
What this study did
Chronic Lymphocytic Leukemia
NCT03462719 · Janssen Research & Development, LLC
2018-04-17 – 2029-04-05 · Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
NCT03701282 · National Cancer Institute (NCI)
2019-02-12 – 2028-05-07 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT01886872 · National Cancer Institute (NCI)
2014-01-15 – 2027-06-24 · Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
What this study did
NCT03737981 · National Cancer Institute (NCI)
2019-01-31 – 2026-12-29 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT01724346 · Pharmacyclics LLC.
2013-12-03 – 2023-08-18 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02863718 · German CLL Study Group
2014-04-30 – 2022-07-11 · Chronic Lymphocytic Leukemia
What this study did
NCT02991638 · The University of Hong Kong
2016-11-01 – 2021-06 · Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas, Chronic Hepatitis B, Lymphoma, Small Lymphocytic, Mantle-Cell Lymphoma, Waldenstrom's Macroglobulinaemia, Follicular Lymphoma
What this study did
NCT01973387 · Janssen Research & Development, LLC
2013-10-28 – 2017-08-11 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Diffuse Large B-Cell Lymphoma
NCT02443077 · National Cancer Institute (NCI)
2016-10-12 – 2026-12-23 · Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
What this study did
Mantle Cell Lymphoma
NCT05431179 · Oncternal Therapeutics, Inc
2023-03 – 2026-12 · Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders, Lymphatic Diseases, Immunoproliferative Disorders, Immune System Diseases, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
What this study did
NCT02858258 · Prof. Dr. M. Dreyling (co-chairman)
2016-07 – 2026-05 · Mantle Cell Lymphoma
What this study did
NCT01646021 · Janssen Research & Development, LLC
2012-12-10 – 2016-12-15 · Mantle Cell Lymphoma
What this study did
Other / comorbidity
NCT02947347 · Pharmacyclics LLC.
2017-01-23 – 2025-06-09 · Follicular Lymphoma
What this study did
NCT03053440 · BeiGene
2017-01-25 – 2022-06-21 · Waldenström's Macroglobulinemia
What this study did
NCT02703272 · Janssen Research & Development, LLC
2016-07-01 – 2021-06-11 · Lymphoma, Non-Hodgkin
What this study did
NCT02165397 · Pharmacyclics LLC.
2014-07-07 – 2019-11-07 · Waldenström's Macroglobulinemia
What this study did
NCT02436668 · Pharmacyclics LLC.
2015-05 – 2019-04-25 · Metastatic Pancreatic Adenocarcinoma
What this study did
NCT02757040 · Peking University People's Hospital
2016-12 – 2018-12 · Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
Phase 2/3 (3)
Chronic Lymphocytic Leukemia
NCT02801578 · M.D. Anderson Cancer Center
2016-07-06 – 2019-01-28 · Chronic Lymphocytic Leukemia
What this study did
Other / comorbidity
NCT04061512 · University College, London
2020-02-03 – 2030-03 · Waldenstrom Macroglobulinemia
What this study did
NCT03642236 · Nanfang Hospital, Southern Medical University
2018-08 – 2023-09 · FLT3-ITD Mutation, Acute Myeloid Leukemia, Brutons Tyrosine Kinase
What this study did
Phase 2 (152)
Chronic Graft-versus-Host Disease
NCT06271616 · Mayo Clinic
2024-12-13 – 2026-05-14 · Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
What this study did
NCT04294641 · National Cancer Institute (NCI)
2021-05-10 – 2024-10-01 · Chronic GVHD
What this study did
NCT05348096 · Hospital Universitario Dr. Jose E. Gonzalez
2022-04-01 – 2023-08-01 · Chronic Graft-versus-host-disease
What this study did
Chronic Lymphocytic Leukemia
NCT02514083 · National Heart, Lung, and Blood Institute (NHLBI)
2015-12-09 – 2034-10-23 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT01500733 · National Heart, Lung, and Blood Institute (NHLBI)
2012-01-05 – 2034-09-30 · Leukemia, Leukemia, Lymphocytyc, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)
What this study did
NCT07738887 · The Lymphoma Academic Research Organisation
2026-12-31 – 2032-06-30 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT05963074 · Janssen Research & Development, LLC
2024-05-30 – 2029-03-19 · Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
What this study did
NCT02007044 · M.D. Anderson Cancer Center
2013-12-06 – 2028-06-30 · Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
What this study did
NCT02629809 · M.D. Anderson Cancer Center
2016-03-18 – 2028-03-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT04685915 · Inhye Ahn
2021-02-18 – 2028-03-01 · Chronic Lymphocytic Leukemia (CLL)
What this study did
NCT06958705 · The First Affiliated Hospital with Nanjing Medical University
2025-12-01 – 2028-02-01 · Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
What this study did
NCT03980002 · Institute of Hematology & Blood Diseases Hospital, China
2019-05-15 – 2027-12-30 · Chronic Lymphocytic Leukemia
What this study did
NCT04758975 · Paolo Ghia
2022-09-19 – 2027-12-30 · Chronic Lymphocytic Leukemia (CLL)
What this study did
NCT04908228 · Paolo Ghia
2021-12-13 – 2027-09-15 · Chronic Lymphocytic Leukemia
What this study did
NCT05672173 · City of Hope Medical Center
2023-06-02 – 2027-08-24 · Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome
What this study did
NCT02756897 · M.D. Anderson Cancer Center
2016-07-07 – 2027-07-01 · Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
What this study did
NCT03128879 · M.D. Anderson Cancer Center
2017-06-16 – 2027-05-31 · Chronic Lymphocytic Leukemia
What this study did
NCT02251548 · Dana-Farber Cancer Institute
2014-10 – 2027-01 · Chronic Lymphocytic Leukemia, Leukemia
What this study did
NCT03513562 · Ohio State University Comprehensive Cancer Center
2019-03-26 – 2026-12-31 · Chronic Lymphocytic Leukemia, Ibrutinib Resistance
What this study did
NCT05694312 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2023-11-24 – 2026-11 · Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Monoclonal B-Cell Lymphocytosis CLL-Type
What this study did
NCT01589302 · Kami Maddocks, MD
2012-05-21 – 2026-10-31 · Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia
What this study did
NCT03226301 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2017-06-23 – 2026-06-21 · Chronic Lymphocytic Leukemia in Relapse, Chronic Lymphocytic Leukemia in Remission
What this study did
NCT02649387 · Mayo Clinic
2016-02-08 – 2026-01-15 · Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
What this study did
NCT03204188 · National Heart, Lung, and Blood Institute (NHLBI)
2017-09-22 – 2026-01-09 · B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Leukemia, Chronic Lymphatic, Leukemia, Chronic Lymphocytic, B-Cell, Leukemia, Lymphocytic, Chronic, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphocytic Leukemia, Chronic, B Cell, Lymphocytic Leukemia, Chronic, B-Cell
What this study did
NCT02518555 · Jennifer Woyach
2016-01-12 – 2026-01-05 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT03734198 · French Innovative Leukemia Organisation
2018-12-19 – 2025-12-19 · Relapsed or Refractory Chronic Lymphocytic Leukemia
What this study did
NCT03708003 · Swiss Cancer Institute
2019-03-11 – 2025-11-30 · Relapsed/Refractory Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Leukemia
What this study did
NCT04754035 · Paolo Ghia
2017-11-08 – 2025-09-01 · Chronic Lymphocytic Leukemia
What this study did
NCT04230304 · Mayo Clinic
2020-11-11 – 2025-02-13 · Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
What this study did
NCT04010968 · French Innovative Leukemia Organisation
2019-09-27 – 2025-01-30 · Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients, Risk-Adapted and MRD-Driven Strategy
What this study did
NCT03207555 · M.D. Anderson Cancer Center
2018-05-23 – 2024-08-02 · Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
What this study did
NCT02232386 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2015-03-02 – 2024-04-16 · Chronic Lymphocyte Leukemia, Adult Patients
What this study did
NCT02388048 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2015-10 – 2024-04-03 · Leukemia, Lymphoblastic, Chronic
What this study did
NCT02910583 · Pharmacyclics LLC.
2016-09-28 – 2024-03-27 · Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02869633 · Vanderbilt-Ingram Cancer Center
2016-11 – 2023-10 · Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Follicular Lymphoma, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma
What this study did
NCT03514017 · H. Lee Moffitt Cancer Center and Research Institute
2019-05-31 – 2023-05-16 · Chronic Lymphocytic Leukemia
What this study did
NCT03280160 · PETHEMA Foundation
2017-09-07 – 2022-09 · Chronic Lymphocytic Leukemia
What this study did
NCT04665115 · Academic and Community Cancer Research United
2020-11-23 – 2022-07-22 · Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Symptomatic COVID-19 Infection Laboratory-Confirmed, Waldenstrom Macroglobulinemia
What this study did
NCT02420912 · M.D. Anderson Cancer Center
2015-06-19 – 2022-02-14 · Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
What this study did
NCT02662296 · Fred Hutchinson Cancer Center
2016-03 – 2022-02 · Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma
What this study did
NCT02332980 · Mayo Clinic
2015-02-19 – 2022-01-04 · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Richter Syndrome, Waldenstrom Macroglobulinemia
What this study did
NCT03045328 · Steven E. Coutre
2017-09-26 – 2021-08-05 · Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
What this study did
NCT03943342 · Kerry Rogers
2020-03-11 – 2021-07-20 · Chronic Lymphocytic Leukemia, Loss of Chromosome 17p
What this study did
NCT03755947 · Grupo Cooperativo de Hemopatías Malignas
2018-12-01 – 2021-02-01 · B-Cell Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)
What this study did
NCT04209621 · National Heart, Lung, and Blood Institute (NHLBI)
2020-07-31 – 2021-01-22 · Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL)
What this study did
NCT02689141 · German CLL Study Group
2016-02-04 – 2020-02-06 · Chronic Lymphocytic Leukemia
What this study did
NCT01109069 · Pharmacyclics LLC.
2010-06 – 2019-04-26 · B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Well-differentiated Lymphocytic Lymphoma, B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Waldenstrom Macroglobulinemia, Burkitt Lymphoma, B-Cell Diffuse Lymphoma
What this study did
Phase 1/2 (54)
Chronic Graft-versus-Host Disease
NCT03689894 · Dartmouth-Hitchcock Medical Center
2019-04-11 – 2021-09-20 · Chronic Graft-versus-host-disease
What this study did
Chronic Lymphocytic Leukemia
NCT07052695 · Inhye Ahn
2025-11-24 – 2032-12-31 · Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma
What this study did
NCT03153202 · Joshua Brody
2017-07-14 – 2028-04 · Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
What this study did
NCT04771507 · Jeanette Lundin
2018-02-23 – 2027-12-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT03331198 · Juno Therapeutics, a Subsidiary of Celgene
2017-11-27 – 2027-11-26 · Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
What this study did
NCT02427451 · Kerry Rogers
2015-08-03 – 2027-04-15 · Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
What this study did
NCT04494503 · Ascentage Pharma Group Inc.
2020-08-31 – 2025-12 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT03088878 · Oncternal Therapeutics, Inc
2018-01-03 – 2024-09-25 · B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
What this study did
NCT02733042 · Celgene
2016-05-11 – 2022-08-21 · Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
NCT02315768 · University of California, San Diego
2015-08-26 – 2022-04-18 · Chronic Lymphocytic Leukemia
What this study did
NCT03572634 · Sumitomo Pharma America, Inc.
2019-06-10 – 2020-01-21 · Chronic Lymphocytic Leukemia, CLL, SLL, Small Lymphocytic Lymphoma
What this study did
NCT02912754 · Sunnybrook Health Sciences Centre
2017-03 – 2019-08 · Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
NCT02677948 · University of Michigan Rogel Cancer Center
2016-10 – 2018-10 · Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
What this study did
NCT02013128 · TG Therapeutics, Inc.
2014-01-06 – 2015-12 · Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
What this study did
NCT01217749 · Pharmacyclics LLC.
2010-12 – 2014-05 · B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocyctic Leukemia, Richter's Transformation
What this study did
Diffuse Large B-Cell Lymphoma
NCT03223610 · National Cancer Institute (NCI)
2018-02-09 – 2029-12-12 · Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
What this study did
NCT06536049 · Yazeed Sawalha
2025-04-02 – 2027-10-31 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
What this study did
NCT03960840 · Novartis Pharmaceuticals
2019-06-26 – 2027-07-24 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
What this study did
NCT04607772 · Karyopharm Therapeutics Inc
2020-11-18 – 2025-12 · Relapsed or Refractory Diffuse Large B-Cell Lymphoma
What this study did
NCT03129828 · Prof. Dr. Clemens Schmitt
2017-03-17 – 2024-11-12 · Diffuse Large B Cell Lymphoma
What this study did
NCT03684694 · ADC Therapeutics S.A.
2018-12-01 – 2022-11-08 · Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
What this study did
NCT02760485 · Incyte Corporation
2016-12-29 – 2022-06-06 · Lymphoma
What this study did
NCT02077166 · Pharmacyclics LLC.
2014-03-13 – 2020-12-17 · Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
What this study did
NCT02401048 · Pharmacyclics LLC.
2015-05 – 2017-11 · Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
What this study did
NCT02142049 · Pharmacyclics LLC.
2014-05 – 2017-08 · Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
What this study did
Mantle Cell Lymphoma
NCT06357676 · OHSU Knight Cancer Institute
2025-05-29 – 2029-11-01 · Mantle Cell Lymphoma
What this study did
NCT02558816 · Nantes University Hospital
2015-10-14 – 2025-05-13 · Mantle Cell Lymphoma
What this study did
NCT03323151 · PrECOG, LLC.
2018-08-13 – 2023-09-07 · Mantle-Cell Lymphoma
What this study did
NCT02927964 · Robert Lowsky
2016-11-07 – 2023-05-18 · Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
What this study did
NCT03877055 · Memorial Sloan Kettering Cancer Center
2019-03-13 – 2022-10-07 · Mantle Cell Lymphoma (MCL)
What this study did
NCT02356458 · Swiss Cancer Institute
2015-08-31 – 2021-03-30 · Mantle Cell Lymphoma
What this study did
Other / comorbidity
NCT04446962 · Institut Curie
2020-10-30 – 2035-08-30 · Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary
What this study did
NCT03328078 · Curis, Inc.
2017-12-28 – 2027-10 · Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
What this study did
NCT04421560 · Dana-Farber Cancer Institute
2020-08-01 – 2027-01-05 · Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
What this study did
NCT03581942 · Memorial Sloan Kettering Cancer Center
2018-08-23 – 2026-02-05 · Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
What this study did
NCT02315326 · Memorial Sloan Kettering Cancer Center
2014-12-08 – 2026-01-28 · Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
What this study did
NCT03379428 · US Oncology Research
2017-11-29 – 2025-01 · Breast Neoplasms, Malignant Neoplasm of Breast
What this study did
NCT02956382 · Georgetown University
2017-03-01 – 2024-03-07 · Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma
What this study did
NCT04522284 · National University Hospital, Singapore
2020-08-20 – 2023-08-01 · Solid Tumor
What this study did
NCT03310619 · Celgene
2017-12-20 – 2023-02-15 · Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
What this study did
NCT02329847 · Janssen Research & Development, LLC
2015-03-11 – 2022-02-09 · Hematologic Neoplasms
What this study did
NCT02321540 · M.D. Anderson Cancer Center
2015-03-31 – 2021-09-16 · Lung Cancer
What this study did
NCT03332498 · H. Lee Moffitt Cancer Center and Research Institute
2018-01-24 – 2021-09-09 · Colon Cancer, Colorectal Cancer, Colorectal Carcinoma, Colon Disease
What this study did
NCT02599324 · Pharmacyclics LLC.
2015-12-01 – 2021-08-20 · Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
What this study did
NCT02899078 · University of California, Davis
2016-11-15 – 2021-02-24 · Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer
What this study did
NCT02562898 · Margaret Tempero
2015-10-12 – 2020-09-01 · Metastatic Pancreatic Adenocarcinoma
What this study did
Phase 1 (88)
Chronic Lymphocytic Leukemia
NCT03422393 · Michael Choi
2018-05-01 – 2028-08 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02160015 · National Cancer Institute (NCI)
2014-05-20 – 2027-08-19 · Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
What this study did
NCT02537613 · Dana-Farber Cancer Institute
2015-12 – 2027-01 · Chronic Lymphocytic Leukemia
What this study did
NCT03447808 · Jennifer Woyach
2018-08-16 – 2026-05-26 · Chronic Lymphocytic Leukemia
What this study did
NCT04781855 · M.D. Anderson Cancer Center
2022-07-14 – 2025-02-21 · Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
What this study did
NCT03400176 · Novartis Pharmaceuticals
2018-04-09 – 2023-09-29 · Chronic Lymphocytic Leukemia (CLL)
What this study did
NCT02268851 · Dana-Farber Cancer Institute
2014-11 – 2022-10 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
What this study did
NCT01886859 · National Cancer Institute (NCI)
2013-04-26 – 2022-09-21 · Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
What this study did
NCT02303392 · Jennifer Woyach
2015-06-09 – 2022-04-18 · Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
What this study did
NCT01644253 · Aptevo Therapeutics
2012-09 – 2021-04-21 · Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
What this study did
NCT03454165 · Dartmouth-Hitchcock Medical Center
2018-03-09 – 2021-01-14 · Chronic Lymphocytic Leukemia
What this study did
NCT02611908 · Michael Choi
2016-06 – 2020-11 · Chronic Lymphocytic Leukemia
What this study did
NCT04043845 · Dana-Farber Cancer Institute
2020-02-03 – 2020-02-03 · Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma
What this study did
NCT02006485 · TG Therapeutics, Inc.
2013-12-13 – 2019-10 · Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
What this study did
NCT02614508 · Emory University
2016-01 – 2019-08 · Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
What this study did
NCT02556892 · Janssen Pharmaceutical K.K.
2015-07-03 – 2018-08-20 · Lymphocytic Leukemia
What this study did
NCT02200848 · Georgetown University
2014-04 – 2017-08-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02381080 · Janssen Research & Development, LLC
2015-05-19 – 2016-06-24 · B-Cell Chronic Lymphocytic Leukemia
What this study did
NCT02109224 · National Cancer Institute (NCI)
2014-09 – 2015-07 · Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, HIV Infection, Intraocular Lymphoma, Multicentric Angiofollicular Lymphoid Hyperplasia, Nodal Marginal Zone Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Plasma Cell Myeloma, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT01292135 · Pharmacyclics LLC.
2011-02 – 2013-05 · B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Diffuse Large B-Cell Lymphoma
NCT04739813 · National Cancer Institute (NCI)
2021-07-09 – 2031-05-07 · Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
What this study did
NCT05211336 · National Cancer Institute (NCI)
2022-04-19 – 2029-06-01 · Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
What this study did
NCT03220022 · National Cancer Institute (NCI)
2018-03-16 – 2027-07-16 · AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
What this study did
NCT01955499 · National Cancer Institute (NCI)
2013-09-24 – 2027-05-06 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma
What this study did
NCT03479268 · City of Hope Medical Center
2018-04-27 – 2026-10-28 · B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
What this study did
NCT03939182 · Memorial Sloan Kettering Cancer Center
2019-05-29 – 2025-04-22 · Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
What this study did
NCT03440567 · City of Hope Medical Center
2018-06-08 – 2024-06-24 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT02756247 · Memorial Sloan Kettering Cancer Center
2016-05-09 – 2022-10-06 · Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma
What this study did
NCT03876028 · Novartis Pharmaceuticals
2019-06-11 – 2021-11-01 · Diffuse Large B-cell Lymphoma
What this study did
NCT03136497 · Hackensack Meridian Health
2017-09-05 – 2020-11-09 · Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
What this study did
NCT02780830 · AstraZeneca
2016-06 – 2019-04 · Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
What this study did
NCT02950220 · Kami Maddocks
2017-01-12 – 2019-01-03 · B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Mediastinal Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma
What this study did
NCT02219737 · National Cancer Institute (NCI)
2014-09-12 – 2017-05-11 · CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
What this study did
Mantle Cell Lymphoma
NCT02159755 · National Cancer Institute (NCI)
2014-08-13 – 2027-04-30 · Recurrent Mantle Cell Lymphoma
What this study did
NCT02446236 · Hackensack Meridian Health
2015-06-18 – 2027-01 · Mantle Cell Lymphoma
What this study did
NCT01479842 · Kami Maddocks, MD
2014-03-26 – 2026-12-01 · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT03295240 · Memorial Sloan Kettering Cancer Center
2017-09-20 – 2024-01-22 · Mantle Cell Lymphoma, Lymphoma
What this study did
NCT03219047 · M.D. Anderson Cancer Center
2018-12-20 – 2023-07-03 · Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
What this study did
NCT02269085 · M.D. Anderson Cancer Center
2015-04-20 – 2018-05-29 · Lymphoma
What this study did
Other / comorbidity
NCT05106296 · Theodore S. Johnson
2022-02-08 – 2029-12-28 · Ependymoma, Medulloblastoma, Glioblastoma, Primary Brain Tumor
What this study did
NCT06788509 · Janssen Research & Development, LLC
2024-12-30 – 2028-12-29 · Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Solid Tumor, Adult, Prostatic Neoplasms, Castration-Resistant
What this study did
NCT07169565 · Institute of Hematology & Blood Diseases Hospital, China
2025-09-01 – 2028-09-01 · Waldenström Macroglobulinemia (WM)
What this study did
NCT07082868 · Memorial Sloan Kettering Cancer Center
2025-08-13 – 2028-08 · Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma, Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)
What this study did
NCT02203526 · National Cancer Institute (NCI)
2014-08-14 – 2028-06-15 · Primary Central Nervous System Lymphoma
What this study did
NCT01829568 · National Cancer Institute (NCI)
2013-06-26 – 2027-06-06 · Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma
What this study did
NCT03703167 · Memorial Sloan Kettering Cancer Center
2019-01-22 – 2026-01-26 · Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
What this study did
NCT03021460 · Mayo Clinic
2017-01-31 – 2025-12-31 · Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
What this study did
NCT04876092 · Janssen Research & Development, LLC
2021-07-28 – 2025-02-13 · Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
What this study did
NCT03702725 · Alliance Foundation Trials, LLC.
2019-08-29 – 2024-10-04 · Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma
What this study did
Phase 4 (5)
Chronic Lymphocytic Leukemia
NCT03190330 · Johnson & Johnson Private Limited
2019-06-26 – 2023-05-03 · Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell
What this study did
Other / comorbidity
NCT07474961 · Anne Louise Tølbøll Sørensen
2027-03 – 2036-12 · Waldenstrom Macroglobulinaemia, Multiple Myeloma
What this study did
NCT03229200 · Pharmacyclics Switzerland GmbH
2017-05-22 – 2027-05-10 · Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor
What this study did
MACE and BTK Inhibitorsnot yet recruiting
NCT07923162 · University Hospital, Caen
2026-12-01 – 2027-03-01 · Hematologic Cancer, MACE, BTK Inhibitors
What this study did
NCT04042376 · Janssen Research & Development, LLC
2019-12-18 – 2024-03-19 · Waldenstrom Macroglobulinemia
What this study did
Used as active comparator (9)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (8)
Chronic Lymphocytic Leukemia
NCT06136559 · Merck Sharp & Dohme LLC
2023-12-13 – 2032-09-07 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02477696 · Acerta Pharma BV
2015-07-28 – 2028-01-03 · Chronic Lymphocytic Leukemia
What this study did
NCT05254743 · Loxo Oncology, Inc.
2022-07-22 – 2028-01 · Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
What this study did
NCT03734016 · BeiGene
2018-11-01 – 2024-02-28 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Graft-versus-Host Disease
NCT03112603 · Incyte Corporation
2017-06-29 – 2022-12-15 · Graft-versus-host Disease (GVHD)
What this study did
Mantle Cell Lymphoma
NCT07377578 · Guangzhou Lupeng Pharmaceutical Company LTD.
2026-02-05 – 2033-01-30 · Mantle Cell Lymphoma
What this study did
NCT04662255 · Loxo Oncology, Inc.
2021-04-08 – 2030-06 · Lymphoma, Mantle-Cell
What this study did
NCT02735876 · Acerta Pharma BV
2016-05 – 2020-06 · Mantle Cell Lymphoma
What this study did
Phase 2 (1)
Other / comorbidity
NCT04840602 · National Cancer Institute (NCI)
2022-01-05 – 2028-03-31 · Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
What this study did
Appears in other studies (6)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (3)
Chronic Lymphocytic Leukemia
NCT02301156 · TG Therapeutics, Inc.
2015-01-27 – 2020-04-01 · Chronic Lymphocytic Leukemia
What this study did
Mantle Cell Lymphoma
NCT03112174 · Pharmacyclics LLC.
2017-06-19 – 2024-06-27 · Mantle-Cell Lymphoma
What this study did
Other / comorbidity
NCT04212013 · Memorial Sloan Kettering Cancer Center
2019-12-23 – 2027-03-18 · Marginal Zone Lymphoma
What this study did
Phase 2 (2)
Chronic Lymphocytic Leukemia
NCT06520098 · VA Office of Research and Development
2025-10-01 – 2030-12-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Mantle Cell Lymphoma
NCT06482684 · Christian Schmidt, MD
2024-02-15 – 2031-12-31 · Mantle Cell Lymphoma
What this study did
Phase 1 (1)
Chronic Lymphocytic Leukemia
NCT03666000 · Imugene Limited
2019-03-11 – 2027-06 · Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Graft-versus-Host Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ibrutinib: this drugApprovedSmall moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
AxatilimabApprovedMonoclonal antibodyCSF-1RWeak signalFeatured results are non-efficacy only in this race
BelumosudilApprovedSmall moleculeRho-associated kinase (ROCK, pan)Weak signal
NCT03640481: Overall Response Rate (ORR) (From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 40.5 months for adult arms and 27.6 months for adolescent arms)): Adult Arm A: Belumosudil 200 mg QD 74 Percentage of participants | Adult Arm B: Belumosudil 200 mg BID 76 Percentage of participants | Adolescent Arm A: Belumosudil 200 mg QD 50 Percentage of participants | Adolescent Arm B: Belumosudil 200 mg BID 100 Percentage of participants
Rilzabrutinib
Approved(overall)
Small moleculeBTK
Reliable signal(overall)
No reviewed efficacy summary in this indication
Ruxolitinib (Jakafi)ApprovedSmall moleculeJAK1/2Partial signal
NCT03112603: Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit (Cycle 7 Day 1 (each cycle was comprised of 4 weeks)): Ruxolitinib 49.7 percentage of participants (95% CI 41.8 to 57.6) | Best Available Therapy 25.6 percentage of participants (95% CI 19.1 to 33)

Upcoming events

(46 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ibrutinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
December 2026 (5)
Phase 1Mantle Cell LymphomaActive not recruiting
Est. primary completion 2026-12-01 · NCT01479842 · CT.gov ↗
What to watch
Phase 1/2Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed CancerRecruiting
Est. primary completion 2026-12-05 · NCT04421560 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2026-12-31 · NCT03513562 · CT.gov ↗
What to watch
Phase 2LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT02436707 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2026-12-31 · NCT01804686 · CT.gov ↗
What to watch
2027 (21)
February 2027 (2)
Phase 4Hematologic Cancer, MACE, BTK InhibitorsNot yet recruiting
Est. primary completion 2027-02-01 · NCT07923162 · CT.gov ↗
What to watch
Phase 2Classical Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-02-15 · NCT02940301 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-03-22 · NCT03710772 · CT.gov ↗
What to watch
April 2027 (2)
Phase 1/2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-04 · NCT03153202 · CT.gov ↗
What to watch
Phase 2Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma …Active not recruiting
Est. primary completion 2027-04 · NCT04450173 · CT.gov ↗
What to watch
May 2027 (2)
Phase 4Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid TumorActive not recruiting
Est. primary completion 2027-05-10 · NCT03229200 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-05-31 · NCT03128879 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone LymphomaActive not recruiting
Est. primary completion 2027-06-15 · NCT03697512 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-06-30 · NCT03960840 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-06-30 · NCT02427620 · CT.gov ↗
What to watch
July 2027 (2)
Phase 1/2Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma …Recruiting
Est. primary completion 2027-07 · NCT03328078 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-07-01 · NCT02756897 · CT.gov ↗
What to watch
August 2027 (3)
Phase 1/2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-08-12 · NCT03223610 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-08-24 · NCT05672173 · CT.gov ↗
What to watch
Phase 1/2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-08-31 · NCT06536049 · CT.gov ↗
What to watch
September 2027 (2)
Phase 3Chronic Lymphoid LeukemiaActive not recruiting
Est. primary completion 2027-09 · NCT04608318 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-09-01 · NCT04234061 · CT.gov ↗
What to watch
November 2027 (2)
Phase 1/2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-11-01 · NCT06357676 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-11-26 · NCT03331198 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-12-01 · NCT06958705 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-12-15 · NCT05963074 · CT.gov ↗
What to watch
2028 (14)
January 2028 (1)
Phase 1Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Solid Tumor …Enrolling by invitation
Est. primary completion 2028-01-19 · NCT06788509 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2028-02-28 · NCT03282396 · CT.gov ↗
What to watch
March 2028 (2)
Phase 1Ependymoma, Medulloblastoma, Glioblastoma, Primary Brain TumorRecruiting
Est. primary completion 2028-03-30 · NCT05106296 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2028-03-31 · NCT02629809 · CT.gov ↗
What to watch
May 2028 (3)
Phase 2Waldenstrom MacroglobulinemiaActive not recruiting
Est. primary completion 2028-05 · NCT04263480 · CT.gov ↗
What to watch
Phase 3Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2028-05-07 · NCT03701282 · CT.gov ↗
What to watch
Phase 2Non-hodgkin LymphomaRecruiting
Est. primary completion 2028-05-31 · NCT05998642 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2028-06-30 · NCT02007044 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2028-07-31 · NCT01880567 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma …Recruiting
Est. primary completion 2028-08 · NCT07082868 · CT.gov ↗
What to watch
September 2028 (2)
Phase 1Waldenström Macroglobulinemia (WM)Not yet recruiting
Est. primary completion 2028-09-01 · NCT07169565 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-09-01 · NCT06649812 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1/2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT07052695 · CT.gov ↗
What to watch
Phase 2Central Nervous System Lymphoma, Secondary Central Nervous System LymphomaActive not recruiting
Est. primary completion 2028-12-31 · NCT03964090 · CT.gov ↗
What to watch
2029 (2)
December 2029 (2)
Phase 2Chronic Lymphocytic LeukemiaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07738887 · CT.gov ↗
What to watch
Phase 2Hairy Cell Leukemia, Hairy Cell Leukemia Variant, Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia VariantActive not recruiting
Est. primary completion 2029-12-31 · NCT01841723 · CT.gov ↗
What to watch
2030 (1)
March 2030 (1)
Phase 2/3Waldenstrom MacroglobulinemiaRecruiting
Est. primary completion 2030-03 · NCT04061512 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
Phase 2Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2032-11 · NCT05283720 · CT.gov ↗
What to watch
2035 (1)
February 2035 (1)
Phase 1/2Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, PrimaryActive not recruiting
Est. primary completion 2035-02-02 · NCT04446962 · CT.gov ↗
What to watch
2036 (1)
December 2036 (1)
Phase 4Waldenstrom Macroglobulinaemia, Multiple MyelomaNot yet recruiting
Est. primary completion 2036-12 · NCT07474961 · CT.gov ↗
What to watch

See the full readout calendar ↗